SCOTTSDALE, Ariz. — Feb. 6, 2025 — Michael S. Gordon, M.D., Chief Medical Officer of HonorHealth Research Institute, today was named a Fellow of the American Society of Clinical Oncology (FASCO), the world’s leading professional organization for physicians and oncology professionals caring for people with cancer.
“The title of FASCO is a recognition bestowed upon ASCO members who have shown extraordinary dedication for their voluntary efforts that benefit the Society, the specialty of oncology, and most importantly, the patients whom we serve,” according to a letter signed by Clifford A. Hudis, M.D., FASCO, ASCO’s Chief Executive Officer.
Mark Slater, Ph.D., Vice President of Research for HonorHealth and CEO of HonorHealth Research Institute, said that without question Dr. Gordon deserves ASCO’s FASCO recognition.
“Dr. Gordon is a powerhouse of innovation whose impact on the quality of research practiced at our Research Institute is beyond measure,” Dr. Slater said. “His FASCO recognition reflects the high degree of caring and compassion for our patients, which he imbues in all of our advanced clinical trials. Plus, he is a highly effective ambassador for the Institute as we navigate our multitude of biomedical science collaborations.
“Dr. Gordon’s remarkable record of accomplishment in advancing new therapies provides hope for cancer patients, reflects his scientific and clinical leadership, and embodies an Institute model of the innovative physician-scientist,” Dr. Slater said. “Dr. Gordon is a recognized leader in the field, attracting patients and collaborators from across the globe to HonorHealth Research Institute to advance tomorrow’s cancer innovations today.”
Dr. Gordon has served as the Chief Medical Officer of the HonorHealth Research Institute since 2021, helping supervise the Research Institute’s five major divisions governing Cancer, Cardiovascular Disease, GI/Bariatrics, Neuroscience and Multispecialty research.
He also is the Research Director of the Multispecialty Research Division, which includes pulmonology, rheumatology, infectious disease (including COVID-19), and other emerging areas of biomedical research. And, as part of the medical staff at HonorHealth since 2000, Dr. Gordon has served on numerous committees servicing the Research Institute’s Clinical Trials Programs.
Dr. Gordon said he was honored and humbled to have been selected as an ASCO Fellow and to have received the vaunted designation of FASCO.
“It is indeed a privilege to be mentioned among some of the nation’s and world’s leading oncologists,” said Dr. Gordon. “I have to believe that this recognition is due in large part to the amazing body of work compiled by all of my extremely talented colleagues at HonorHealth Research Institute.”
Dr. Gordon’s record of leadership
Dr. Gordon is a respected innovator and leader in a variety of biomedical research areas and has helped develop a number of new cancer treatments. He is a board certified specialist in both solid and blood cancers, approaching his work from a unique perspective: not only as a physician, but also as a scientist and as patient, having been diagnosed and treated for an early stage pancreatic cancer in 2021. His overarching goals are to promote not only the best science but also provide the best care for patients.
He also has served in key leadership capacities for the Arizona Center for Cancer Care, the University of Arizona Cancer Center and the University of Arizona College of Medicine-Phoenix.
Prior to moving to Arizona, Dr. Gordon worked and trained at major institutions, including: Indiana University School of Medicine, Cornell University Medical College, Memorial Sloan-Kettering Cancer Center, and the University of Chicago Hospital and Clinics.
Dr. Gordon’s new FASCO title will be recognized May 31 at the 2025 annual meeting of ASCO at McCormick Place Convention Center in Chicago.
Founded in 1964 and based in Alexandria, Vir., ASCO represents a network of more than 50,000 oncology professionals worldwide dedicated to providing the highest-quality resources in education, policy, the pioneering of clinical research, and advancing care for patients with cancer.
# # #
About the HonorHealth Research Institute
HonorHealth Research Institute is an international destination that is at the forefront of providing patients with a better quality of life through its clinical trials and innovative treatment options. Headquartered in Scottsdale, Arizona, the institute’s team of physicians and researchers collaborate with experts from across the nation to offer life-changing therapies, drugs and devices. At HonorHealth Research Institute, patients have access to tomorrow’s health innovations, today. Learn more at: HonorHealth.com/research.